S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:VYGR

Voyager Therapeutics Competitors

$5.58
+0.04 (+0.72 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.37
Now: $5.58
$5.75
50-Day Range
$5.54
MA: $7.47
$9.04
52-Week Range
$5.37
Now: $5.58
$14.62
Volume558,730 shs
Average Volume528,591 shs
Market Capitalization$210.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8

Competitors

Voyager Therapeutics (NASDAQ:VYGR) Vs. ALGS, CLLS, TCRR, STRO, ADAP, and VXRT

Should you be buying VYGR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Voyager Therapeutics, including Aligos Therapeutics (ALGS), Cellectis (CLLS), TCR2 Therapeutics (TCRR), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), and Vaxart (VXRT).

Voyager Therapeutics (NASDAQ:VYGR) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Voyager Therapeutics and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
Aligos TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Voyager Therapeutics and Aligos Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08602.43
Aligos Therapeutics00403.00

Voyager Therapeutics currently has a consensus price target of $12.9615, indicating a potential upside of 132.29%. Aligos Therapeutics has a consensus price target of $30.50, indicating a potential upside of 41.60%. Given Voyager Therapeutics' higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Aligos Therapeutics.

Valuation and Earnings

This table compares Voyager Therapeutics and Aligos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million2.01$-43,600,000.00($1.21)-4.61
Aligos TherapeuticsN/AN/AN/AN/AN/A

Aligos Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics.

Summary

Voyager Therapeutics beats Aligos Therapeutics on 5 of the 9 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 33.3% of Cellectis shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Voyager Therapeutics and Cellectis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
Cellectis-110.52%-23.56%-16.69%

Analyst Ratings

This is a summary of current recommendations and price targets for Voyager Therapeutics and Cellectis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08602.43
Cellectis11302.40

Voyager Therapeutics currently has a consensus price target of $12.9615, indicating a potential upside of 132.29%. Cellectis has a consensus price target of $24.25, indicating a potential upside of 25.58%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Cellectis.

Valuation and Earnings

This table compares Voyager Therapeutics and Cellectis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million2.01$-43,600,000.00($1.21)-4.61
Cellectis$22.99 million35.69$-102,090,000.00($2.41)-8.01

Voyager Therapeutics has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Voyager Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.

Summary

Voyager Therapeutics beats Cellectis on 10 of the 14 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and TCR2 Therapeutics (NASDAQ:TCRR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by insiders. Comparatively, 28.0% of TCR2 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Voyager Therapeutics and TCR2 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
TCR2 TherapeuticsN/A-35.51%-34.02%

Analyst Ratings

This is a summary of current recommendations and price targets for Voyager Therapeutics and TCR2 Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08602.43
TCR2 Therapeutics00703.00

Voyager Therapeutics currently has a consensus price target of $12.9615, indicating a potential upside of 132.29%. TCR2 Therapeutics has a consensus price target of $39.2857, indicating a potential upside of 63.28%. Given Voyager Therapeutics' higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than TCR2 Therapeutics.

Valuation and Earnings

This table compares Voyager Therapeutics and TCR2 Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million2.01$-43,600,000.00($1.21)-4.61
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21

Voyager Therapeutics has higher revenue and earnings than TCR2 Therapeutics. TCR2 Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Voyager Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, TCR2 Therapeutics has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500.

Summary

TCR2 Therapeutics beats Voyager Therapeutics on 7 of the 13 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Voyager Therapeutics and Sutro Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
Sutro Biopharma27.60%-41.86%-29.50%

Insider and Institutional Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of Sutro Biopharma shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by insiders. Comparatively, 28.9% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Voyager Therapeutics and Sutro Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million2.01$-43,600,000.00($1.21)-4.61
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35

Voyager Therapeutics has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Voyager Therapeutics and Sutro Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08602.43
Sutro Biopharma01602.86

Voyager Therapeutics currently has a consensus price target of $12.9615, indicating a potential upside of 132.29%. Sutro Biopharma has a consensus price target of $23.3333, indicating a potential upside of 15.00%. Given Voyager Therapeutics' higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Sutro Biopharma.

Volatility & Risk

Voyager Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Summary

Voyager Therapeutics beats Sutro Biopharma on 7 of the 13 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Voyager Therapeutics and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
Adaptimmune Therapeutics-3,858.14%-44.94%-33.70%

Insider & Institutional Ownership

78.8% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are held by institutional investors. 23.9% of Voyager Therapeutics shares are held by insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Voyager Therapeutics and Adaptimmune Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million2.01$-43,600,000.00($1.21)-4.61
Adaptimmune Therapeutics$1.12 million692.36$-137,160,000.00($1.32)-3.80

Voyager Therapeutics has higher revenue and earnings than Adaptimmune Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Voyager Therapeutics and Adaptimmune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08602.43
Adaptimmune Therapeutics03202.40

Voyager Therapeutics currently has a consensus target price of $12.9615, indicating a potential upside of 132.29%. Adaptimmune Therapeutics has a consensus target price of $15.50, indicating a potential upside of 209.38%. Given Adaptimmune Therapeutics' higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Voyager Therapeutics.

Risk and Volatility

Voyager Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Summary

Voyager Therapeutics beats Adaptimmune Therapeutics on 9 of the 14 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Voyager Therapeutics and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
Vaxart-281.50%-84.90%-44.67%

Insider & Institutional Ownership

78.8% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Vaxart shares are held by institutional investors. 23.9% of Voyager Therapeutics shares are held by insiders. Comparatively, 7.3% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Voyager Therapeutics and Vaxart's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million2.01$-43,600,000.00($1.21)-4.61
Vaxart$9.86 million70.71$-18,650,000.00($0.86)-6.88

Vaxart has lower revenue, but higher earnings than Voyager Therapeutics. Vaxart is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Voyager Therapeutics and Vaxart, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08602.43
Vaxart00203.00

Voyager Therapeutics currently has a consensus target price of $12.9615, indicating a potential upside of 132.29%. Vaxart has a consensus target price of $15.00, indicating a potential upside of 153.38%. Given Vaxart's stronger consensus rating and higher probable upside, analysts clearly believe Vaxart is more favorable than Voyager Therapeutics.

Risk and Volatility

Voyager Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500.

Summary

Voyager Therapeutics beats Vaxart on 9 of the 14 factors compared between the two stocks.


Voyager Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54+12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31+4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06+6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29+4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01+4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92+7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86+7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29+6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61+8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16+7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02+3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28+17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16+9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02+7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13+6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90+2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83+12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44+2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45+6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59+1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14+4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43+2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35+7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75+0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54+4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50+7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82+2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18+10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30+2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71+6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25+7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20+3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81+11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53+12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24+8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50+7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47+0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18+9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39+11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84+6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06+7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23+5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Axcella Health logo
AXLA
Axcella Health
1.6$5.51+3.1%$206.85 millionN/A-2.56
INmune Bio logo
INMB
INmune Bio
1.5$15.37+22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43+6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
Genfit logo
GNFT
Genfit
1.3$4.87+2.7%$189.24 million$45.88 million-2.47
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.18+6.7%$186.70 millionN/A-8.76Gap Up
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$4.23+14.2%$178.75 million$1.45 million-1.48Earnings Announcement
Analyst Upgrade
Increase in Short Interest
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.90+0.7%$178.60 millionN/A-2.27Gap Up
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$5.35+4.3%$168.68 million$20,000.000.00Decrease in Short Interest
Gap Down
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.